Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France. Show more

Location: 50 rue de Dijon, Daix, 21121, France | Website: https://inventivapharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

802.4M

52 Wk Range

$1.53 - $6.50

Previous Close

$5.77

Open

$5.41

Volume

89,083

Day Range

$5.31 - $5.70

Enterprise Value

728.2M

Cash

96.91M

Avg Qtr Burn

-21.48M

Insider Ownership

0.00%

Institutional Own.

5.16%

Qtr Updated

12/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lanifibranor (Pan-PPAR) Details Metabolic dysfunction-associated steatohepatitis (MASH)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lanifibranor + empagliflozin Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cedirogant (ABBV-157) (60RORy) Details Psoriasis, Kidney cancer, Carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Odiparcil (GAG) Details Rare diseases, Rare genetic disease, Mucopolysaccharidoses, Mucopolysaccharidosis type IV, Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.